Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK rearrange ALK D1203N ALK E1210K ALK G1269A||lung non-small cell carcinoma||resistant||Lorlatinib||Case Reports/Case Series||Actionable||In a clinical study, ALK G1269A was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK E1210K and D1203N, who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).||29650534|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|